Identification

Name
Verapamil
Accession Number
DB00661  (APRD00335)
Type
Small Molecule
Groups
Approved
Description

A calcium channel blocker that is a class IV anti-arrhythmia agent.

Structure
Thumb
Synonyms
  • Iproveratril
  • Vérapamil
  • Verapamil
  • Verapamilo
  • Verapamilum
External IDs
CP-16,533-1 / D-365
Product Ingredients
IngredientUNIICASInChI Key
Verapamil hydrochlorideV3888OEY5R152-11-4DOQPXTMNIUCOSY-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CalanTablet, film coated80 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
CalanTablet, film coated120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1984-09-10Not applicableUs
Calan SRTablet, film coated, extended release120 mg/1OralG.D. Searle LLC Division of Pfizer Inc1991-03-06Not applicableUs
Calan SRTablet, film coated, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1986-12-16Not applicableUs00025 1891 51 nlmimage10 4d132699
Calan SRTablet, film coated, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1989-12-15Not applicableUs
Covera-HSTablet, extended release180 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release240 mgOralPfizer1997-11-132013-02-15Canada
Covera-HSTablet, extended release240 mg/1OralG.D. Searle LLC Division of Pfizer Inc1996-02-262016-10-13Us
Covera-HSTablet, extended release180 mgOralPfizer1997-11-132013-02-15Canada
Isoptin Inj 2.5mg/mlLiquid2.5 mgIntravenousAbbott1984-12-312007-07-31Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-verapamil - 120mgTablet120 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
Alti-verapamil - 80mgTablet80 mgOralAltimed Pharma Inc.1990-12-312004-08-03Canada
Apo-verap SRTablet, extended release180 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release120 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap SRTablet, extended release240 mgOralApotex Corporation2003-04-24Not applicableCanada
Apo-verap Tab 80mgTablet80 mgOralApotex Corporation1989-12-31Not applicableCanada
Apo-verap Tablet 120mgTablet120 mgOralApotex Corporation1989-12-31Not applicableCanada
Dom-verapamil SR 240mg TabletsTablet, extended release240 mgOralDominion Pharmacal1999-12-16Not applicableCanada
Mylan-verapamilTablet80 mgOralMylan Pharmaceuticals1998-05-25Not applicableCanada
Mylan-verapamilTablet120 mgOralMylan Pharmaceuticals1998-05-11Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2005-05-27Not applicableUs
TarkaVerapamil hydrochloride (180 mg) + Trandolapril (2 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs0074 329020180814 13942 gpsp61
TarkaVerapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-01-01Not applicableUs
TarkaVerapamil hydrochloride (180 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (2 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (4 mg)Tablet, extended releaseOralBgp Pharma Ulc2002-07-15Not applicableCanada
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (2 mg/1)Tablet, film coated, extended releaseOralAbbvie1996-10-22Not applicableUs
TarkaVerapamil hydrochloride (240 mg/1) + Trandolapril (4 mg/1)Tablet, film coated, extended releaseOralPhysicians Total Care, Inc.2009-06-25Not applicableUs00074 3290 13 nlmimage10 ec1d766b
TarkaVerapamil hydrochloride (240 mg) + Trandolapril (1 mg)Tablet, extended releaseOralAbbott2002-07-152010-11-12Canada
International/Other Brands
Bosoptin (Bosnalijek) / Isoptin (Abbott) / Verisop (Gerard) / Vermin (Ratiopharm) / Vermine (Pharmasant) / Verogalid (Ivax) / Verogalid ER (Ivax) / Verpamil (Mylan) / Vertab (Trinity-Chiesi) / Vetrimil (CCPC) / Zolvera (Rosemont)
Categories
UNII
CJ0O37KU29
CAS number
52-53-9
Weight
Average: 454.6016
Monoisotopic: 454.283157714
Chemical Formula
C27H38N2O4
InChI Key
SGTNSNPWRIOYBX-UHFFFAOYSA-N
InChI
InChI=1S/C27H38N2O4/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6/h9-12,17-18,20H,8,13-16H2,1-7H3
IUPAC Name
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile
SMILES
COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1

Pharmacology

Indication

For the treatment of hypertension, angina, and cluster headache prophylaxis.

Associated Conditions
Pharmacodynamics

Verapamil is an L-type calcium channel blocker that also has antiarrythmic activity. The R-enantiomer is more effective at reducing blood pressure compared to the S-enantiomer. However, the S-enantiomer is 20 times more potent than the R-enantiomer at prolonging the PR interval in treating arrhythmias.

Mechanism of action

Verapamil inhibits voltage-dependent calcium channels. Specifically, its effect on L-type calcium channels in the heart causes a reduction in ionotropy and chronotropy, thuis reducing heart rate and blood pressure. Verapamil's mechanism of effect in cluster headache is thought to be linked to its calcium-channel blocker effect, but which channel subtypes are involved is presently not known.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1F
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-3
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-4
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1I
inhibitor
Human
UVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
UVoltage-dependent N-type calcium channel subunit alpha-1B
inhibitor
Human
UVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
USodium channel protein type 5 subunit alpha
other
Human
UATP-sensitive inward rectifier potassium channel 11
inhibitor
Human
USodium-dependent serotonin transporter
other/unknown
Human
UAlpha-1A adrenergic receptor
antagonist
Human
UAlpha-1B adrenergic receptor
antagonist
Human
UAlpha-1D adrenergic receptor
antagonist
Human
Absorption

90%

Volume of distribution
Not Available
Protein binding

90%

Metabolism
Route of elimination

Approximately 70% of an administered dose is excreted as metabolites in the urine and 16% or more in the feces within 5 days. About 3% to 4% is excreted in the urine as unchanged drug.

Half life

2.8-7.4 hours

Clearance
Not Available
Toxicity

LD50=8 mg/kg (i.v. in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Verapamil Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Beta-1 adrenergic receptor---(G;G) / (C;G)G > CEffect Directly StudiedPatients with this genotype require a lower dosage of verapamil to achieve a favourable rate-control response when treating atrial fibrillation.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Verapamil.Experimental
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Verapamil.Experimental, Investigational
16-BromoepiandrosteroneThe metabolism of 16-Bromoepiandrosterone can be decreased when combined with Verapamil.Investigational
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Verapamil.Investigational
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Verapamil.Experimental
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Verapamil.Experimental, Illicit
5-androstenedioneThe metabolism of 5-androstenedione can be decreased when combined with Verapamil.Experimental, Illicit
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Verapamil.Investigational
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Verapamil.Investigational
AbediterolThe therapeutic efficacy of Abediterol can be decreased when used in combination with Verapamil.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Verapamil.Approved, Investigational
AbirateroneThe serum concentration of Verapamil can be increased when it is combined with Abiraterone.Approved
AcebutololVerapamil may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Verapamil.Approved, Investigational
AcepromazineAcepromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Vet Approved
AcetaminophenThe serum concentration of Verapamil can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigitoxin.Approved
AcetyldigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Acetyldigoxin.Experimental
Acetylsalicylic acidVerapamil may increase the anticoagulant activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Verapamil.Approved
AdrafinilThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Verapamil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Verapamil.Approved
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Verapamil.Experimental, Investigational
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Verapamil.Investigational
AlbendazoleThe serum concentration of Verapamil can be increased when it is combined with Albendazole.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Verapamil.Approved
AlcuroniumVerapamil may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Verapamil.Experimental, Investigational
AlectinibThe serum concentration of Verapamil can be increased when it is combined with Alectinib.Approved, Investigational
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Verapamil.Approved, Illicit
AlfuzosinAlfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Verapamil.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Verapamil.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Verapamil.Approved
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Verapamil.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Verapamil.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Verapamil.Approved, Withdrawn
AloxiprinVerapamil may increase the anticoagulant activities of Aloxiprin.Experimental
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Verapamil.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
AlprenololVerapamil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Verapamil.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Verapamil.Approved, Investigational
AmcinonideThe metabolism of Amcinonide can be decreased when combined with Verapamil.Approved
AmibegronThe therapeutic efficacy of Amibegron can be decreased when used in combination with Verapamil.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Verapamil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Verapamil.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Verapamil.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Verapamil.Approved
Aminosalicylic AcidVerapamil may increase the anticoagulant activities of Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of bradycardia can be increased when Verapamil is combined with Amiodarone.Approved, Investigational
AmitrazThe therapeutic efficacy of Amitraz can be decreased when used in combination with Verapamil.Vet Approved
AmitriptylineAmitriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
AmlodipineThe risk or severity of hypotension can be increased when Verapamil is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Verapamil.Approved, Illicit
AmodiaquineThe serum concentration of Verapamil can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineAmoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
Amphotericin BVerapamil may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Verapamil.Approved, Investigational
AmsacrineThe serum concentration of Verapamil can be increased when it is combined with Amsacrine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Verapamil is combined with Amyl Nitrite.Approved
AndrostenedioneThe metabolism of Androstenedione can be decreased when combined with Verapamil.Experimental, Illicit
AnisodamineVerapamil may increase the hypotensive activities of Anisodamine.Investigational
AnnamycinThe serum concentration of Verapamil can be increased when it is combined with Annamycin.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Verapamil.Approved, Investigational
ApalutamideThe serum concentration of Verapamil can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Verapamil.Approved, Investigational
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Verapamil.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Verapamil.Approved, Investigational
AprepitantThe serum concentration of Verapamil can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Aranidipine.Approved, Investigational
ArbutamineThe therapeutic efficacy of Arbutamine can be decreased when used in combination with Verapamil.Approved
ArformoterolThe therapeutic efficacy of Arformoterol can be decreased when used in combination with Verapamil.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Verapamil.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Verapamil.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Verapamil.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Verapamil.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Verapamil.Approved, Nutraceutical
AsenapineAsenapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
AstemizoleThe serum concentration of Verapamil can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Verapamil.Approved, Investigational, Withdrawn
AtazanavirThe metabolism of Verapamil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololVerapamil may increase the hypotensive activities of Atenolol.Approved
AtorvastatinAtorvastatin can cause a decrease in the absorption of Verapamil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AtovaquoneThe metabolism of Atovaquone can be decreased when combined with Verapamil.Approved
AtracuriumVerapamil may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateVerapamil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Verapamil.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Verapamil.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Verapamil.Approved, Investigational
AzelastineThe serum concentration of Verapamil can be increased when it is combined with Azelastine.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe serum concentration of Verapamil can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The serum concentration of Verapamil can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Verapamil can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe metabolism of Balaglitazone can be decreased when combined with Verapamil.Investigational
BalsalazideVerapamil may increase the anticoagulant activities of Balsalazide.Approved, Investigational
BambuterolThe therapeutic efficacy of Bambuterol can be decreased when used in combination with Verapamil.Approved, Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Verapamil.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Verapamil.Experimental
BarbitalBarbital may increase the hypotensive activities of Verapamil.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Verapamil.Approved, Investigational
BarnidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Barnidipine.Approved
Beclomethasone dipropionateThe metabolism of Beclomethasone dipropionate can be decreased when combined with Verapamil.Approved, Investigational
BedaquilineThe metabolism of Bedaquiline can be decreased when combined with Verapamil.Approved
BefunololVerapamil may increase the hypotensive activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Verapamil.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Verapamil.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Verapamil is combined with Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Verapamil.Approved
BenidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Verapamil.Approved, Illicit
BenzquinamideThe serum concentration of Verapamil can be increased when it is combined with Benzquinamide.Withdrawn
Benzyl alcoholThe serum concentration of Verapamil can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of hypotension can be increased when Verapamil is combined with Bepridil.Approved, Withdrawn
BeractantVerapamil may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Verapamil.Approved, Vet Approved
BetaxololVerapamil may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Verapamil.Approved
BevantololBevantolol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Verapamil.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Verapamil.Approved, Investigational
BicalutamideThe serum concentration of Verapamil can be increased when it is combined with Bicalutamide.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Verapamil.Approved, Investigational
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Verapamil.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Verapamil is combined with Bioallethrin.Approved, Experimental
Biricodar dicitrateThe serum concentration of Verapamil can be increased when it is combined with Biricodar dicitrate.Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Verapamil.Approved
BisoprololVerapamil may increase the hypotensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Verapamil.Approved
BitolterolThe therapeutic efficacy of Bitolterol can be decreased when used in combination with Verapamil.Withdrawn
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Verapamil.Approved, Investigational
BoceprevirThe metabolism of Verapamil can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololVerapamil may increase the hypotensive activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Verapamil.Approved, Investigational
BosentanThe serum concentration of Verapamil can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Verapamil.Approved
Brefeldin AThe serum concentration of Verapamil can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Verapamil.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Verapamil.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Verapamil.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Verapamil.Approved, Investigational
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Verapamil.Approved
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Verapamil.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Verapamil.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Verapamil.Approved, Illicit, Investigational
BromocriptineVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Verapamil.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Verapamil.Approved
BucindololBucindolol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
BufuralolVerapamil may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Verapamil is combined with Bumetanide.Approved
BunazosinBunazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Verapamil.Approved, Investigational
BupranololVerapamil may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Verapamil can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Verapamil.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Verapamil.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Verapamil.Approved, Investigational
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Verapamil.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Verapamil.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Verapamil.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Verapamil.Approved, Investigational
CaffeineThe serum concentration of Verapamil can be increased when it is combined with Caffeine.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Verapamil.Approved, Nutraceutical
Calcium AcetateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Phosphate.Approved
CalfactantVerapamil may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Verapamil.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Verapamil.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Verapamil is combined with Candesartan cilexetil.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Verapamil.Approved, Investigational
CaptoprilThe serum concentration of Verapamil can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Verapamil.Approved, Investigational
Carbaspirin calciumVerapamil may increase the anticoagulant activities of Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Verapamil.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Verapamil.Approved
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Verapamil is combined with Carboxyamidotriazole.Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Verapamil.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Verapamil.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Verapamil.Approved, Investigational
CaroverineThe risk or severity of hypotension can be increased when Verapamil is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
CarteololVerapamil may increase the hypotensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Verapamil.Approved, Investigational, Nutraceutical, Vet Approved
CefoperazoneThe serum concentration of Verapamil can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Verapamil can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Verapamil.Approved, Investigational
CeliprololVerapamil may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
CeritinibVerapamil may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Verapamil.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Verapamil.Approved, Investigational
CevimelineThe metabolism of Cevimeline can be decreased when combined with Verapamil.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Verapamil.Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Verapamil.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Verapamil.Approved, Illicit, Investigational
ChlormadinoneThe metabolism of Chlormadinone can be decreased when combined with Verapamil.Experimental
ChloroformThe serum concentration of Verapamil can be increased when it is combined with Chloroform.Vet Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Verapamil.Approved
ChlorpromazineChlorpromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational, Vet Approved
ChlorprothixeneThe serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Verapamil.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Verapamil.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Verapamil.Approved, Investigational
CiglitazoneThe metabolism of Ciglitazone can be decreased when combined with Verapamil.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Cilnidipine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Verapamil.Approved, Investigational
CimetidineThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Verapamil.Approved
CinnarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe metabolism of Verapamil can be decreased when combined with Ciprofloxacin.Approved, Investigational
CirazolineThe therapeutic efficacy of Cirazoline can be decreased when used in combination with Verapamil.Experimental
CisaprideThe metabolism of Cisapride can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
CisatracuriumVerapamil may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Verapamil.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Verapamil.Approved
ClarithromycinThe metabolism of Verapamil can be decreased when combined with Clarithromycin.Approved
ClenbuterolThe therapeutic efficacy of Clenbuterol can be decreased when used in combination with Verapamil.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Clevidipine.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Verapamil.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Verapamil.Approved, Illicit
ClobetasolThe metabolism of Clobetasol can be decreased when combined with Verapamil.Approved, Investigational
Clobetasol propionateThe metabolism of Clobetasol propionate can be decreased when combined with Verapamil.Approved
ClobetasoneThe metabolism of Clobetasone can be decreased when combined with Verapamil.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Verapamil.Approved, Investigational
ClofazimineThe serum concentration of Verapamil can be increased when it is combined with Clofazimine.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Verapamil.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Verapamil.Investigational
ClomipramineThe serum concentration of Verapamil can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Verapamil.Approved, Illicit
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Verapamil.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Verapamil.Approved
CloranololVerapamil may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Verapamil.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be decreased when combined with Verapamil.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Verapamil.Approved, Illicit
ClotrimazoleThe metabolism of Verapamil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
CobicistatThe metabolism of Verapamil can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Verapamil.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Verapamil.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Verapamil.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Verapamil.Approved
Concanamycin AThe serum concentration of Verapamil can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Verapamil.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Verapamil.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Verapamil.Approved, Investigational
CorticosteroneThe metabolism of Corticosterone can be decreased when combined with Verapamil.Experimental
CorticotropinThe metabolism of Corticotropin can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Verapamil.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Verapamil.Approved
CurcuminThe metabolism of Verapamil can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Verapamil is combined with Cyclandelate.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Verapamil.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
CymarinVerapamil may increase the atrioventricular blocking (AV block) activities of Cymarin.Experimental
Cyproterone acetateThe serum concentration of Verapamil can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Verapamil.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil.Approved
DabrafenibThe serum concentration of Verapamil can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Verapamil can be increased when it is combined with Daclatasvir.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Verapamil.Approved, Investigational
DanazolThe metabolism of Verapamil can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Verapamil.Approved, Investigational, Withdrawn
DantroleneDantrolene may increase the hyperkalemic activities of Verapamil.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Verapamil.Approved
DapiprazoleDapiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Verapamil.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Verapamil.Approved, Investigational
DarodipineThe risk or severity of hypotension can be increased when Verapamil is combined with Darodipine.Experimental
DarunavirThe metabolism of Verapamil can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Verapamil.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Verapamil.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Verapamil.Approved, Investigational
DeferasiroxThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Verapamil.Approved, Investigational
DelamanidThe metabolism of Delamanid can be decreased when combined with Verapamil.Approved, Investigational
DelavirdineThe metabolism of Verapamil can be decreased when combined with Delavirdine.Approved
DemegestoneThe metabolism of Demegestone can be decreased when combined with Verapamil.Approved
DersalazineVerapamil may increase the anticoagulant activities of Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Verapamil.Approved
DesipramineThe serum concentration of Verapamil can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideVerapamil may increase the atrioventricular blocking (AV block) activities of Deslanoside.Approved
DesmethylsertralineThe serum concentration of Verapamil can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe metabolism of Desogestrel can be decreased when combined with Verapamil.Approved
DesonideThe metabolism of Desonide can be decreased when combined with Verapamil.Approved, Investigational
Desoxycorticosterone acetateThe metabolism of Desoxycorticosterone acetate can be decreased when combined with Verapamil.Approved
Desoxycorticosterone PivalateThe metabolism of Desoxycorticosterone Pivalate can be decreased when combined with Verapamil.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Verapamil.Approved, Investigational
DetomidineThe therapeutic efficacy of Detomidine can be decreased when used in combination with Verapamil.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Verapamil.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe metabolism of Dexamethasone isonicotinate can be decreased when combined with Verapamil.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Verapamil.Approved
DexlansoprazoleThe metabolism of Dexlansoprazole can be decreased when combined with Verapamil.Approved, Investigational
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Verapamil.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Verapamil is combined with Dexniguldipine.Experimental
DexrabeprazoleThe metabolism of Dexrabeprazole can be decreased when combined with Verapamil.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Verapamil.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Dexverapamil.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Verapamil.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Diclofenamide.Approved, Investigational
DicoumarolThe metabolism of Dicoumarol can be decreased when combined with Verapamil.Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Verapamil.Approved
Diethyl etherThe serum concentration of Verapamil can be increased when it is combined with Diethyl ether.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Verapamil.Approved, Investigational
DiflunisalVerapamil may increase the anticoagulant activities of Diflunisal.Approved, Investigational
DifluocortoloneThe metabolism of Difluocortolone can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
DifluprednateThe metabolism of Difluprednate can be decreased when combined with Verapamil.Approved
DigitoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Digitoxin.Approved, Investigational
DigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Digoxin.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Verapamil.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Verapamil.Approved, Illicit
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Verapamil.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Verapamil.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Verapamil.Experimental
DihydroergotamineVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Dihydroergotamine.Approved, Investigational
DiltiazemThe risk or severity of hypotension can be increased when Verapamil is combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Verapamil is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe metabolism of Diphenadione can be decreased when combined with Verapamil.Experimental
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Verapamil.Approved
DipyridamoleThe risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Verapamil.Approved
DisopyramideThe risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Verapamil.Approved
DL-MethylephedrineThe therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Verapamil.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Verapamil.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Verapamil.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Verapamil.Approved
DofequidarThe serum concentration of Verapamil can be increased when it is combined with Dofequidar.Experimental, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Verapamil.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Verapamil.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Verapamil.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Verapamil.Approved
DopexamineThe therapeutic efficacy of Dopexamine can be decreased when used in combination with Verapamil.Approved, Investigational
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Verapamil.Approved
DosulepinThe metabolism of Verapamil can be decreased when combined with Dosulepin.Approved
DotarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Dotarizine.Investigational
DovitinibThe serum concentration of Verapamil can be increased when it is combined with Dovitinib.Investigational
DoxacuriumVerapamil may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinDoxazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
DoxepinDoxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
DoxofyllineThe therapeutic efficacy of Doxofylline can be decreased when used in combination with Verapamil.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Verapamil.Approved, Investigational
DoxycyclineThe metabolism of Verapamil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DroperidolDroperidol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Vet Approved
DrospirenoneThe metabolism of Drospirenone can be decreased when combined with Verapamil.Approved
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Verapamil.Approved, Investigational
DuloxetineVerapamil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Verapamil.Approved, Investigational
DydrogesteroneThe metabolism of Dydrogesterone can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
EconazoleThe serum concentration of Verapamil can be increased when it is combined with Econazole.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Verapamil.Approved
EfavirenzThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Verapamil.Approved
EfonidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Efonidipine.Approved, Investigational
ElacridarThe serum concentration of Verapamil can be increased when it is combined with Elacridar.Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Verapamil.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Verapamil.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Verapamil.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Verapamil.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Verapamil.Approved
EmopamilThe risk or severity of hypotension can be increased when Verapamil is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Verapamil.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Verapamil.Approved
EnasidenibThe serum concentration of Verapamil can be increased when it is combined with Enasidenib.Approved, Investigational
EncorafenibThe metabolism of Encorafenib can be decreased when combined with Verapamil.Approved, Investigational
EnoxacinThe metabolism of Verapamil can be decreased when combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Verapamil can be decreased when it is combined with Enzalutamide.Approved
EpanololVerapamil may increase the hypotensive activities of Epanolol.Experimental
EperisoneThe risk or severity of hypotension can be increased when Verapamil is combined with Eperisone.Approved, Investigational
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Verapamil.Approved, Nutraceutical, Withdrawn
EphedrineThe therapeutic efficacy of Ephedrine can be decreased when used in combination with Verapamil.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Verapamil.Approved, Investigational
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Verapamil.Approved, Vet Approved
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Verapamil.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Verapamil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Eprosartan.Approved
EquileninThe metabolism of Equilenin can be decreased when combined with Verapamil.Experimental
EquilinThe metabolism of Equilin can be decreased when combined with Verapamil.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Verapamil.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Verapamil.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Verapamil.Approved
ErgotamineVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Verapamil.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Verapamil.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
EsatenololVerapamil may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Verapamil.Approved, Investigational
EsmololVerapamil may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe serum concentration of Verapamil can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Verapamil.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Verapamil can be increased when it is combined with Estramustine.Approved, Investigational
EstriolThe serum concentration of Estriol can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Verapamil.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Verapamil.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Verapamil.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Verapamil.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe therapeutic efficacy of Etafedrine can be decreased when used in combination with Verapamil.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Verapamil.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Verapamil.Approved
EthosuximideThe risk or severity of hypotension can be increased when Verapamil is combined with Ethosuximide.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be decreased when combined with Verapamil.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Verapamil.Approved, Illicit
EthynodiolThe metabolism of Ethynodiol can be decreased when combined with Verapamil.Experimental
Ethynodiol diacetateThe metabolism of Ethynodiol diacetate can be decreased when combined with Verapamil.Approved
EtilefrineThe therapeutic efficacy of Etilefrine can be decreased when used in combination with Verapamil.Withdrawn
EtizolamThe metabolism of Etizolam can be decreased when combined with Verapamil.Approved
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Verapamil.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Verapamil.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Verapamil.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Verapamil.Approved, Investigational
EtravirineThe serum concentration of Verapamil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Verapamil.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Verapamil.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Verapamil.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Verapamil.Approved, Investigational
FelbamateThe metabolism of Felbamate can be decreased when combined with Verapamil.Approved
FelodipineThe risk or severity of hypotension can be increased when Verapamil is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Verapamil is combined with Fendiline.Withdrawn
FenofibrateThe serum concentration of Verapamil can be increased when it is combined with Fenofibrate.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Verapamil.Approved
FenoterolThe therapeutic efficacy of Fenoterol can be decreased when used in combination with Verapamil.Approved, Investigational
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Verapamil.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Verapamil.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Verapamil.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Verapamil.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Verapamil.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Verapamil.Approved
FingolimodThe risk or severity of bradycardia can be increased when Verapamil is combined with Fingolimod.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Verapamil is combined with Fish oil.Approved, Nutraceutical
FlecainideThe risk or severity of adverse effects can be increased when Verapamil is combined with Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Verapamil is combined with Flibanserin.Approved, Investigational
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Verapamil.Approved
FluconazoleThe serum concentration of Verapamil can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe metabolism of Fludrocortisone can be decreased when combined with Verapamil.Approved, Investigational
FluindioneThe metabolism of Fluindione can be decreased when combined with Verapamil.Approved, Investigational
FlumethasoneThe metabolism of Flumethasone can be decreased when combined with Verapamil.Approved, Vet Approved
FlunarizineThe risk or severity of hypotension can be increased when Verapamil is combined with Flunarizine.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Verapamil.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Verapamil.Approved, Illicit
Fluocinolone AcetonideThe metabolism of Fluocinolone Acetonide can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
FluocinonideThe metabolism of Fluocinonide can be decreased when combined with Verapamil.Approved, Investigational
FluocortoloneThe metabolism of Fluocortolone can be decreased when combined with Verapamil.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Verapamil.Approved, Investigational
FluoxetineThe serum concentration of Verapamil can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational, Withdrawn
FluphenazineThe serum concentration of Verapamil can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe metabolism of Fluprednidene can be decreased when combined with Verapamil.Approved, Withdrawn
FluprednisoloneThe metabolism of Fluprednisolone can be decreased when combined with Verapamil.Approved
FlurandrenolideThe metabolism of Flurandrenolide can be decreased when combined with Verapamil.Approved
FlurazepamThe serum concentration of Verapamil can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Verapamil is combined with Fluspirilene.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Verapamil.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Verapamil.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Verapamil.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Verapamil.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Verapamil.Experimental
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Verapamil.Approved
FluvoxamineThe metabolism of Verapamil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe therapeutic efficacy of Formoterol can be decreased when used in combination with Verapamil.Approved, Investigational
FosamprenavirThe metabolism of Verapamil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Verapamil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Verapamil.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Verapamil.Approved, Investigational
FostamatinibThe risk or severity of hypotension, dyspepsia, and headache can be increased when Fostamatinib is combined with Verapamil.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Verapamil.Approved, Investigational
FurazolidoneFurazolidone may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Verapamil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Verapamil can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of hypotension can be increased when Verapamil is combined with Gabapentin.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Verapamil.Approved
GallamineVerapamil may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideVerapamil may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GallopamilThe risk or severity of hypotension can be increased when Verapamil is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Verapamil.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Verapamil.Approved
GenisteinThe serum concentration of Verapamil can be increased when it is combined with Genistein.Investigational
GestodeneThe metabolism of Gestodene can be decreased when combined with Verapamil.Approved, Investigational
GestrinoneThe metabolism of Gestrinone can be decreased when combined with Verapamil.Approved
GitoformateVerapamil may increase the atrioventricular blocking (AV block) activities of Gitoformate.Experimental
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Verapamil.Approved, Investigational
GlipizideThe metabolism of Glipizide can be decreased when combined with Verapamil.Approved, Investigational
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Verapamil.Approved
GlycerinThe serum concentration of Verapamil can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Verapamil.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Verapamil.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Verapamil.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Verapamil.Approved, Investigational, Withdrawn
GuacetisalVerapamil may increase the anticoagulant activities of Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Verapamil.Approved, Investigational
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Verapamil.Approved, Investigational
HalcinonideThe metabolism of Halcinonide can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Verapamil.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Verapamil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Verapamil.Approved, Vet Approved
HarmalineHarmaline may increase the orthostatic hypotensive activities of Verapamil.Experimental
HE3286The metabolism of HE3286 can be decreased when combined with Verapamil.Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Verapamil.Approved
HexoprenalineThe therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Verapamil.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Higenamine can be decreased when used in combination with Verapamil.Investigational
HistamineThe metabolism of Histamine can be decreased when combined with Verapamil.Approved, Investigational
HM-30181The serum concentration of Verapamil can be increased when it is combined with HM-30181.Experimental
HycanthoneThe serum concentration of Verapamil can be increased when it is combined with Hycanthone.Approved, Investigational
HydracarbazineHydracarbazine may increase the orthostatic hypotensive activities of Verapamil.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Verapamil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Verapamil.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Verapamil.Approved, Vet Approved
Hydrocortisone aceponateThe metabolism of Hydrocortisone aceponate can be decreased when combined with Verapamil.Experimental, Vet Approved
Hydrocortisone acetateThe metabolism of Hydrocortisone acetate can be decreased when combined with Verapamil.Approved, Vet Approved
Hydrocortisone butyrateThe metabolism of Hydrocortisone butyrate can be decreased when combined with Verapamil.Approved, Vet Approved
Hydrocortisone cypionateThe metabolism of Hydrocortisone cypionate can be decreased when combined with Verapamil.Approved, Vet Approved
Hydrocortisone phosphateThe metabolism of Hydrocortisone phosphate can be decreased when combined with Verapamil.Approved, Vet Approved
Hydrocortisone probutateThe metabolism of Hydrocortisone probutate can be decreased when combined with Verapamil.Approved, Vet Approved
Hydrocortisone succinateThe metabolism of Hydrocortisone succinate can be decreased when combined with Verapamil.Approved
Hydrocortisone valerateThe metabolism of Hydrocortisone valerate can be decreased when combined with Verapamil.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Verapamil.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Verapamil.Approved, Illicit
HydroxychloroquineThe serum concentration of Verapamil can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyprogesteroneThe metabolism of Hydroxyprogesterone can be decreased when combined with Verapamil.Experimental
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Verapamil.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Verapamil.Approved
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Verapamil.Approved
IbuprofenThe serum concentration of Verapamil can be increased when it is combined with Ibuprofen.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Verapamil.Approved, Investigational
IdelalisibThe metabolism of Verapamil can be decreased when combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Verapamil resulting in a loss in efficacy.Approved
IloperidoneIloperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Verapamil.Approved, Investigational
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Verapamil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Verapamil.Investigational
ImipramineImipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Verapamil.Approved, Investigational
IndacaterolThe therapeutic efficacy of Indacaterol can be decreased when used in combination with Verapamil.Approved
IndapamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Indapamide.Approved
IndenololVerapamil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Verapamil can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Verapamil can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminIndoramin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Verapamil.Approved, Investigational
IpecacThe metabolism of Ipecac can be decreased when combined with Verapamil.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Verapamil.Approved
IproniazidIproniazid may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Verapamil.Approved, Investigational
IsavuconazoleThe serum concentration of Verapamil can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Verapamil can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the orthostatic hypotensive activities of Verapamil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Verapamil.Approved
IsoetarineThe therapeutic efficacy of Isoetarine can be decreased when used in combination with Verapamil.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Verapamil.Approved, Vet Approved
IsomethepteneThe therapeutic efficacy of Isometheptene can be decreased when used in combination with Verapamil.Approved
IsoniazidThe metabolism of Verapamil can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe therapeutic efficacy of Isoprenaline can be decreased when used in combination with Verapamil.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Verapamil.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Verapamil is combined with Isradipine.Approved, Investigational
ItraconazoleThe metabolism of Verapamil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Verapamil.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Verapamil.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Verapamil.Approved, Investigational
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Verapamil.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Verapamil.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Verapamil.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Verapamil.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Verapamil.Approved, Investigational
KetoconazoleThe metabolism of Verapamil can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolLabetalol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
LacidipineVerapamil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideVerapamil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Verapamil.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Verapamil.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Verapamil.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Verapamil is combined with Lamotrigine.Approved, Investigational
Lanatoside CVerapamil may increase the atrioventricular blocking (AV block) activities of Lanatoside C.Experimental
LandiololVerapamil may increase the hypotensive activities of Landiolol.Investigational
LaniquidarThe serum concentration of Verapamil can be increased when it is combined with Laniquidar.Investigational
LanreotideVerapamil may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Verapamil.Approved, Investigational
LapatinibThe serum concentration of Verapamil can be increased when it is combined with Lapatinib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Verapamil.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Verapamil.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Verapamil.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Verapamil.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Verapamil.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Verapamil.Approved, Investigational
LeuprolideThe metabolism of Leuprolide can be decreased when combined with Verapamil.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Verapamil is combined with Levetiracetam.Approved, Investigational
LevobetaxololVerapamil may increase the hypotensive activities of Levobetaxolol.Approved, Investigational
LevobunololVerapamil may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Verapamil.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Verapamil.Approved
LevodopaVerapamil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Verapamil.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Verapamil.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Verapamil.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Verapamil.Approved, Investigational
LevosalbutamolThe therapeutic efficacy of Levosalbutamol can be decreased when used in combination with Verapamil.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Verapamil.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Verapamil.Approved
LidocaineThe serum concentration of Verapamil can be increased when it is combined with Lidocaine.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Verapamil is combined with Lidoflazine.Experimental
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Verapamil.Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Verapamil.Approved
LinezolidLinezolid may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
LiothyronineThe metabolism of Liothyronine can be decreased when combined with Verapamil.Approved, Vet Approved
LiotrixThe metabolism of Liotrix can be decreased when combined with Verapamil.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Verapamil.Approved, Investigational
Lithium cationVerapamil may increase the neurotoxic activities of Lithium cation.Experimental
LobeglitazoneThe metabolism of Lobeglitazone can be decreased when combined with Verapamil.Approved, Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Verapamil.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Verapamil is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Verapamil.Approved, Investigational
LonafarnibThe serum concentration of Verapamil can be increased when it is combined with Lonafarnib.Investigational
LoperamideThe risk or severity of hypotension can be increased when Verapamil is combined with Loperamide.Approved
LopinavirThe metabolism of Verapamil can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Verapamil can be increased when it is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Verapamil.Approved
LorpiprazoleThe serum concentration of Verapamil can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Verapamil.Approved
LoteprednolThe metabolism of Loteprednol can be decreased when combined with Verapamil.Approved
LovastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Verapamil is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Verapamil can be increased when it is combined with Loxapine.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Verapamil.Approved, Investigational
LucinactantVerapamil may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Verapamil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Verapamil can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Lumefantrine can be decreased when combined with Verapamil.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Verapamil.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Verapamil.Approved, Investigational
LynestrenolThe metabolism of Lynestrenol can be decreased when combined with Verapamil.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Verapamil.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Verapamil.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Verapamil.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Verapamil.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Verapamil.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Verapamil.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Verapamil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Verapamil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe risk or severity of hypotension can be increased when Verapamil is combined with Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Verapamil.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Verapamil.Approved, Investigational
MebanazineMebanazine may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Verapamil.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Verapamil.Approved, Investigational
MedetomidineThe therapeutic efficacy of Medetomidine can be decreased when used in combination with Verapamil.Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Verapamil.Experimental, Investigational
MedrogestoneThe metabolism of Medrogestone can be decreased when combined with Verapamil.Approved
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Verapamil.Approved, Investigational
MedrysoneThe metabolism of Medrysone can be decreased when combined with Verapamil.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Verapamil.Approved, Investigational
Megestrol acetateThe serum concentration of Verapamil can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe metabolism of Melengestrol can be decreased when combined with Verapamil.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Verapamil.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Verapamil.Approved
MentholThe risk or severity of hypotension can be increased when Verapamil is combined with Menthol.Approved
MephentermineThe therapeutic efficacy of Mephentermine can be decreased when used in combination with Verapamil.Approved
MepindololVerapamil may increase the hypotensive activities of Mepindolol.Experimental
MeprednisoneThe metabolism of Meprednisone can be decreased when combined with Verapamil.Approved, Investigational
MesalazineVerapamil may increase the anticoagulant activities of Mesalazine.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Verapamil.Approved
MetaraminolThe therapeutic efficacy of Metaraminol can be decreased when used in combination with Verapamil.Approved, Investigational
MetergolineThe metabolism of Metergoline can be decreased when combined with Verapamil.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Verapamil.Approved
MethadoneThe serum concentration of Verapamil can be increased when it is combined with Methadone.Approved
MethamphetamineThe therapeutic efficacy of Methamphetamine can be decreased when used in combination with Verapamil.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Verapamil.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Verapamil is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Verapamil.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Verapamil.Approved
MethotrimeprazineMethotrimeprazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
MethoxamineThe therapeutic efficacy of Methoxamine can be decreased when used in combination with Verapamil.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Verapamil.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
MethoxyphenamineThe therapeutic efficacy of Methoxyphenamine can be decreased when used in combination with Verapamil.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Verapamil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Verapamil.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Verapamil.Approved
Methyl salicylateVerapamil may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Verapamil.Approved
Methylene blueMethylene blue may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Verapamil.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Verapamil.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Verapamil.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Verapamil.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Verapamil.Approved
MetildigoxinVerapamil may increase the atrioventricular blocking (AV block) activities of Metildigoxin.Experimental
MetipranololVerapamil may increase the hypotensive activities of Metipranolol.Approved
MetocurineVerapamil may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideVerapamil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Verapamil.Approved, Investigational
MetronidazoleThe serum concentration of Verapamil can be increased when it is combined with Metronidazole.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Verapamil.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Verapamil.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Verapamil is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Verapamil can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Verapamil can be increased when it is combined with Midazolam.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Verapamil.Approved
MidodrineVerapamil may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe metabolism of Verapamil can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Verapamil can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the orthostatic hypotensive activities of Verapamil.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Verapamil.Approved, Vet Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Verapamil.Approved, Investigational
MirabegronThe therapeutic efficacy of Mirabegron can be decreased when used in combination with Verapamil.Approved
MirodenafilThe risk or severity of hypotension, dyspepsia, and headache can be increased when Mirodenafil is combined with Verapamil.Investigational
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Verapamil.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Verapamil.Approved
MitotaneThe serum concentration of Verapamil can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Verapamil.Approved, Investigational
MivacuriumVerapamil may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
ModafinilThe serum concentration of Verapamil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Moexipril.Approved
MometasoneThe metabolism of Mometasone can be decreased when combined with Verapamil.Approved, Vet Approved
Mometasone furoateThe metabolism of Mometasone furoate can be decreased when combined with Verapamil.Approved, Vet Approved
MonensinThe serum concentration of Verapamil can be increased when it is combined with Monensin.Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Verapamil.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Verapamil.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Verapamil.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Verapamil.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Verapamil.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Verapamil.Approved, Investigational
NadololVerapamil may increase the hypotensive activities of Nadolol.Approved
NafcillinThe therapeutic efficacy of Verapamil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilThe risk or severity of hypotension can be increased when Verapamil is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Verapamil.Approved
NaloxoneThe metabolism of Verapamil can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe metabolism of Naltrexone can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Verapamil.Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Verapamil.Approved, Investigational
NebivololVerapamil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Withdrawn
NelfinavirThe metabolism of Verapamil can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Verapamil.Approved, Vet Approved
NeratinibThe serum concentration of Verapamil can be increased when it is combined with Neratinib.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Verapamil is combined with Nesiritide.Approved, Investigational
NetoglitazoneThe metabolism of Netoglitazone can be decreased when combined with Verapamil.Experimental
NetupitantThe serum concentration of Verapamil can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Verapamil can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
NicardipineNicardipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
NicergolineNicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Verapamil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Verapamil.Approved
NifedipineThe risk or severity of hypotension can be increased when Verapamil is combined with Nifedipine.Approved
NigericinThe serum concentration of Verapamil can be increased when it is combined with Nigericin.Experimental
NiguldipineNiguldipine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Experimental
NilotinibThe metabolism of Verapamil can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe risk or severity of hypotension can be increased when Verapamil is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Verapamil is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Verapamil is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Verapamil.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Verapamil.Approved
NisoldipineThe risk or severity of hypotension can be increased when Verapamil is combined with Nisoldipine.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Verapamil.Approved
NitrendipineThe risk or severity of hypotension can be increased when Verapamil is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Verapamil.Approved
NitroaspirinVerapamil may increase the anticoagulant activities of Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Verapamil is combined with Nitroglycerin.Approved, Investigational
NitroprussideVerapamil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Verapamil.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Verapamil.Approved
NomegestrolThe metabolism of Nomegestrol can be decreased when combined with Verapamil.Approved
Nomegestrol acetateThe metabolism of Nomegestrol acetate can be decreased when combined with Verapamil.Approved, Investigational
NorelgestrominThe metabolism of Norelgestromin can be decreased when combined with Verapamil.Approved, Investigational
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Verapamil.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Verapamil.Approved
NorethynodrelThe metabolism of Norethynodrel can be decreased when combined with Verapamil.Approved
NorfenefrineThe therapeutic efficacy of Norfenefrine can be decreased when used in combination with Verapamil.Experimental
NorgestimateThe metabolism of Norgestimate can be decreased when combined with Verapamil.Approved, Investigational
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Verapamil.Approved
NorgestrienoneThe metabolism of Norgestrienone can be decreased when combined with Verapamil.Experimental
NortriptylineNortriptyline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Verapamil.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Verapamil.Approved, Investigational
OctamoxinOctamoxin may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
OctopamineThe therapeutic efficacy of Octopamine can be decreased when used in combination with Verapamil.Experimental
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Verapamil.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Verapamil.Investigational
OlanzapineOlanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Verapamil.Approved
OleandrinVerapamil may increase the atrioventricular blocking (AV block) activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.Approved, Investigational
OlodaterolThe therapeutic efficacy of Olodaterol can be decreased when used in combination with Verapamil.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
OlsalazineVerapamil may increase the anticoagulant activities of Olsalazine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Verapamil.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Verapamil.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Verapamil.Approved
ONT-093The serum concentration of Verapamil can be increased when it is combined with ONT-093.Investigational
OpiumThe metabolism of Opium can be decreased when combined with Verapamil.Approved, Illicit
OrciprenalineThe therapeutic efficacy of Orciprenaline can be decreased when used in combination with Verapamil.Approved
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Verapamil.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Verapamil.Approved, Investigational
OtiloniumThe risk or severity of hypotension can be increased when Verapamil is combined with Otilonium.Experimental, Investigational
OuabainVerapamil may increase the atrioventricular blocking (AV block) activities of Ouabain.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Verapamil.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Verapamil.Approved
OxprenololVerapamil may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Verapamil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Verapamil is combined with Oxycodone.Approved, Illicit, Investigational
OxyfedrineThe therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Verapamil.Experimental
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Verapamil.Approved, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Verapamil.Investigational, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Verapamil.Approved, Vet Approved
PalbociclibThe serum concentration of Verapamil can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Verapamil.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Verapamil.Approved, Investigational
PancuroniumVerapamil may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Verapamil.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Verapamil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.Approved, Investigational
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Verapamil.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Verapamil.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Verapamil.Approved
PargylinePargyline may increase the orthostatic hypotensive activities of Verapamil.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Verapamil.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Verapamil.Approved, Investigational
ParoxetineThe serum concentration of Verapamil can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotideVerapamil may increase the bradycardic activities of Pasireotide.Approved
Patent BlueThe therapeutic efficacy of Verapamil can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.Approved
Peginterferon alfa-2bThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololVerapamil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of hypotension can be increased when Verapamil is combined with Penfluridol.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Verapamil.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Verapamil.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Verapamil.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Verapamil.Approved, Investigational, Vet Approved
PentoxifyllineThe risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Verapamil.Approved, Investigational
PerampanelThe metabolism of Perampanel can be decreased when combined with Verapamil.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Verapamil.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Verapamil.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Verapamil.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Verapamil.Approved
PeruvosideVerapamil may increase the atrioventricular blocking (AV block) activities of Peruvoside.Experimental
PethidineThe serum concentration of Verapamil can be increased when it is combined with Pethidine.Approved
PF-00610355The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Verapamil.Investigational
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Verapamil.Withdrawn
PhendimetrazineThe therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Verapamil.Approved, Illicit
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Verapamil.Approved
PheniprazinePheniprazine may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Verapamil.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Verapamil.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Verapamil.Vet Approved
PhenoxybenzaminePhenoxybenzamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
PhenoxypropazinePhenoxypropazine may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Verapamil.Approved, Investigational
PhentolaminePhentolamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
Phenyl aminosalicylateVerapamil may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Verapamil.Approved
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Verapamil.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Verapamil.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Verapamil.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Verapamil.Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Verapamil.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Verapamil.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Verapamil.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Verapamil.Approved
PinaveriumThe risk or severity of hypotension can be increased when Verapamil is combined with Pinaverium.Approved
PindololVerapamil may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Verapamil.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Verapamil.Approved, Investigational
PipecuroniumVerapamil may increase the neuromuscular blocking activities of Pipecuronium.Approved
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Verapamil.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Verapamil.Approved, Investigational
PirbuterolThe therapeutic efficacy of Pirbuterol can be decreased when used in combination with Verapamil.Approved
PirlindolePirlindole may increase the orthostatic hypotensive activities of Verapamil.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Verapamil.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Verapamil.Approved, Investigational
PivhydrazinePivhydrazine may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
PizotifenVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Verapamil.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Verapamil.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Verapamil.Approved
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Verapamil.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Verapamil.Approved, Vet Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Verapamil.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Verapamil.Approved, Investigational
Poractant alfaVerapamil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Verapamil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Verapamil.Approved, Investigational
PractololVerapamil may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Verapamil.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Verapamil.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Verapamil.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Verapamil.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Verapamil.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
PrazosinPrazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
PrednicarbateThe metabolism of Prednicarbate can be decreased when combined with Verapamil.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Verapamil.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Verapamil.Approved, Vet Approved
PrednylideneThe metabolism of Prednylidene can be decreased when combined with Verapamil.Experimental
PregabalinThe metabolism of Pregabalin can be decreased when combined with Verapamil.Approved, Illicit, Investigational
PregnenoloneThe metabolism of Pregnenolone can be decreased when combined with Verapamil.Approved, Experimental, Investigational
PrenalterolThe therapeutic efficacy of Prenalterol can be decreased when used in combination with Verapamil.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Verapamil is combined with Prenylamine.Withdrawn
PrimaquineThe serum concentration of Verapamil can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Verapamil.Approved, Vet Approved
ProcaterolThe therapeutic efficacy of Procaterol can be decreased when used in combination with Verapamil.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.Approved, Vet Approved
ProgesteroneThe serum concentration of Verapamil can be increased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Verapamil.Approved
PromazinePromazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Vet Approved
PromegestoneThe metabolism of Promegestone can be decreased when combined with Verapamil.Experimental
PromethazineThe serum concentration of Verapamil can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Verapamil.Approved
PropericiazineVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazinePropiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
PropiverineVerapamil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe serum concentration of Verapamil can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropranololVerapamil may increase the hypotensive activities of Propranolol.Approved, Investigational
ProscillaridinVerapamil may increase the atrioventricular blocking (AV block) activities of Proscillaridin.Experimental
ProtokylolThe therapeutic efficacy of Protokylol can be decreased when used in combination with Verapamil.Approved, Vet Approved
ProtriptylineThe serum concentration of Verapamil can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Verapamil.Approved
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Verapamil.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Verapamil.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Verapamil.Approved, Illicit
QuercetinThe serum concentration of Verapamil can be increased when it is combined with Quercetin.Experimental, Investigational
QuetiapineQuetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
QuinacrineThe serum concentration of Verapamil can be increased when it is combined with Quinacrine.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Verapamil is combined with Quinapril.Approved, Investigational
QuingestanolThe metabolism of Quingestanol can be decreased when combined with Verapamil.Experimental
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Verapamil.Approved, Investigational
QuinineThe metabolism of Verapamil can be increased when combined with Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Verapamil.Approved, Investigational
RacepinephrineThe therapeutic efficacy of Racepinephrine can be decreased when used in combination with Verapamil.Approved
RactopamineThe therapeutic efficacy of Ractopamine can be decreased when used in combination with Verapamil.Vet Approved
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Verapamil.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Verapamil.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Verapamil.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Verapamil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Verapamil.Approved, Investigational
RapacuroniumVerapamil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the orthostatic hypotensive activities of Verapamil.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Verapamil.Investigational
ReboxetineThe serum concentration of Verapamil can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Verapamil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Verapamil.Approved
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Verapamil.Approved, Investigational
ReproterolThe therapeutic efficacy of Reproterol can be decreased when used in combination with Verapamil.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Verapamil.Approved, Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Verapamil.Approved
Reversin 121The serum concentration of Verapamil can be increased when it is combined with Reversin 121.Experimental
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Verapamil.Experimental
RifabutinThe metabolism of Rifabutin can be decreased when combined with Verapamil.Approved, Investigational
RifampicinThe metabolism of Verapamil can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Verapamil can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Verapamil can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Verapamil.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Verapamil.Approved, Investigational
RimexoloneThe metabolism of Verapamil can be increased when combined with Rimexolone.Approved
RimiterolThe therapeutic efficacy of Rimiterol can be decreased when used in combination with Verapamil.Experimental
RimonabantThe metabolism of Rimonabant can be decreased when combined with Verapamil.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Verapamil is combined with Riociguat.Approved
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Verapamil.Approved, Investigational
RitobegronThe therapeutic efficacy of Ritobegron can be decreased when used in combination with Verapamil.Investigational
RitodrineThe therapeutic efficacy of Ritodrine can be decreased when used in combination with Verapamil.Approved, Investigational
RitonavirThe metabolism of Verapamil can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Verapamil.Approved
RivastigmineVerapamil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RivoglitazoneThe metabolism of Rivoglitazone can be decreased when combined with Verapamil.Experimental, Investigational
RocuroniumVerapamil may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Verapamil can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Verapamil.Approved, Investigational
RomifidineThe therapeutic efficacy of Romifidine can be decreased when used in combination with Verapamil.Vet Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Verapamil.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Verapamil.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Verapamil.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Verapamil.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Verapamil.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Verapamil.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Verapamil.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Verapamil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Verapamil.Approved
SafinamideSafinamide may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
SafrazineSafrazine may increase the orthostatic hypotensive activities of Verapamil.Withdrawn
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Verapamil.Approved, Vet Approved
Salicylic acidVerapamil may increase the anticoagulant activities of Salicylic acid.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Verapamil can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.Approved
SaquinavirThe metabolism of Verapamil can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Verapamil can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Verapamil.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Verapamil.Approved, Vet Approved
SelegilineSelegiline may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Verapamil is combined with Seletracetam.Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Verapamil.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Verapamil.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Verapamil.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Verapamil.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Verapamil can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Verapamil.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Verapamil.Approved, Illicit, Investigational, Withdrawn
SildenafilThe risk or severity of hypotension, dyspepsia, and headache can be increased when Sildenafil is combined with Verapamil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Verapamil.Approved
SiltuximabThe serum concentration of Verapamil can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Verapamil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Verapamil is combined with Simvastatin.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Verapamil.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Verapamil.Approved, Investigational
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Verapamil.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Verapamil.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Verapamil.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Verapamil.Approved
SolabegronThe therapeutic efficacy of Solabegron can be decreased when used in combination with Verapamil.Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Verapamil.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Verapamil.Approved, Investigational
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Verapamil.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Verapamil.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Verapamil.Approved
SotalolVerapamil may increase the hypotensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Verapamil.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Verapamil.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Verapamil.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.Approved
St. John's WortThe serum concentration of Verapamil can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Verapamil.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Verapamil.Experimental
StaurosporineThe serum concentration of Verapamil can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Verapamil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Verapamil.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Verapamil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Verapamil.Approved
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Verapamil.Approved
SulfasalazineVerapamil may increase the anticoagulant activities of Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Verapamil.Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Verapamil.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Verapamil.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.Approved, Investigational
SynephrineThe therapeutic efficacy of Synephrine can be decreased when used in combination with Verapamil.Experimental
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Verapamil.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Verapamil.Approved
TacrineThe serum concentration of Tacrine can be increased when it is combined with Verapamil.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Verapamil.Approved, Investigational
TadalafilThe risk or severity of hypotension, dyspepsia, and headache can be increased when Tadalafil is combined with Verapamil.Approved, Investigational
TalinololVerapamil may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Verapamil.Approved
TamsulosinTamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
TariquidarThe serum concentration of Verapamil can be increased when it is combined with Tariquidar.Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Verapamil.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Verapamil.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Verapamil.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Verapamil.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Verapamil.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Verapamil can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Verapamil can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Verapamil can be increased when it is combined with Telmisartan.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Verapamil.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Verapamil.Approved
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Verapamil.Approved
TerazosinTerazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved
TerbutalineThe therapeutic efficacy of Terbutaline can be decreased when used in combination with Verapamil.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Verapamil.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Verapamil.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Verapamil.Experimental
TeriflunomideThe serum concentration of Verapamil can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe risk or severity of hypotension can be increased when Verapamil is combined with Terodiline.Experimental
TertatololVerapamil may increase the hypotensive activities of Tertatolol.Experimental
TesmilifeneThe serum concentration of Verapamil can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Verapamil can be increased when it is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe serum concentration of Verapamil can be increased when it is combined with Testosterone cypionate.Approved
Testosterone enanthateThe serum concentration of Verapamil can be increased when it is combined with Testosterone enanthate.Approved
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Verapamil.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe serum concentration of Verapamil can be increased when it is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Verapamil.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of hypotension can be increased when Verapamil is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Verapamil is combined with Tetrandrine.Experimental
TetryzolineThe therapeutic efficacy of Tetryzoline can be decreased when used in combination with Verapamil.Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Verapamil.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Verapamil.Approved, Investigational, Withdrawn
TheophyllineThe risk or severity of hypotension, dyspepsia, and headache can be increased when Theophylline is combined with Verapamil.Approved
ThiamylalThiamylal may increase the hypotensive activities of Verapamil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Verapamil.Approved, Vet Approved
ThioproperazineThioproperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Verapamil.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Verapamil.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Verapamil.Approved, Investigational
TianeptineThe metabolism of Tianeptine can be decreased when combined with Verapamil.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Verapamil.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Verapamil.Approved
TimololVerapamil may increase the hypotensive activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Verapamil.Approved, Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Verapamil.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Verapamil.Approved
TipifarnibThe serum concentration of Verapamil can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe metabolism of Verapamil can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Verapamil.Approved, Investigational
TocilizumabThe serum concentration of Verapamil can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Verapamil.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Verapamil.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Verapamil.Approved, Investigational
TolazolineTolazoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Verapamil.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Verapamil is combined with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the orthostatic hypotensive activities of Verapamil.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Verapamil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Verapamil.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Verapamil.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Verapamil.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.Approved
ToremifeneThe serum concentration of Verapamil can be increased when it is combined with Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Verapamil.Approved, Investigational
TramadolThe metabolism of Tramadol can be decreased when combined with Verapamil.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Verapamil.Approved
TranilastThe risk or severity of hypotension can be increased when Verapamil is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Verapamil.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Verapamil.Approved, Investigational
TrazodoneTrazodone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Verapamil.Approved, Investigational, Nutraceutical
TretoquinolThe therapeutic efficacy of Tretoquinol can be decreased when used in combination with Verapamil.Experimental
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Verapamil.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Verapamil.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Verapamil.Approved, Investigational
TrifluoperazineTrifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved, Investigational
TriflupromazineThe serum concentration of Verapamil can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrilostaneThe metabolism of Trilostane can be decreased when combined with Verapamil.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinTrimazosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Verapamil is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Verapamil is combined with Trimethadione.Approved
TrimethoprimThe serum concentration of Verapamil can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Verapamil.Investigational, Withdrawn
Trolamine salicylateVerapamil may increase the anticoagulant activities of Trolamine salicylate.Approved
TroleandomycinThe metabolism of Verapamil can be decreased when combined with Troleandomycin.Approved
TubocurarineVerapamil may increase the neuromuscular blocking activities of Tubocurarine.Approved
TulobuterolThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Verapamil.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Verapamil.Approved, Investigational, Nutraceutical
UdenafilThe risk or severity of hypotension, dyspepsia, and headache can be increased when Udenafil is combined with Verapamil.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Verapamil.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Verapamil.Approved
UrapidilUrapidil may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Verapamil.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Verapamil.Experimental
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Verapamil.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Verapamil.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Verapamil.Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Verapamil.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Verapamil.Investigational
VardenafilThe risk or severity of hypotension, dyspepsia, and headache can be increased when Vardenafil is combined with Verapamil.Approved
VecuroniumVerapamil may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Verapamil.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Verapamil.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Verapamil.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Verapamil.Investigational
VilanterolThe therapeutic efficacy of Vilanterol can be decreased when used in combination with Verapamil.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Verapamil.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Verapamil.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Verapamil.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Verapamil.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Verapamil.Approved, Investigational
VinpocetineThe risk or severity of hypotension can be increased when Verapamil is combined with Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Verapamil.Approved, Investigational
VoacamineThe serum concentration of Verapamil can be increased when it is combined with Voacamine.Approved, Investigational
VorapaxarThe serum concentration of Verapamil can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe metabolism of Verapamil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Verapamil.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Verapamil.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Verapamil.Approved
WIN 55212-2The risk or severity of hypotension can be increased when Verapamil is combined with WIN 55212-2.Experimental
XamoterolThe therapeutic efficacy of Xamoterol can be decreased when used in combination with Verapamil.Experimental
XylazineThe therapeutic efficacy of Xylazine can be decreased when used in combination with Verapamil.Vet Approved
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Verapamil.Approved, Investigational
YohimbineThe serum concentration of Verapamil can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Verapamil can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Verapamil.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Verapamil.Approved, Illicit, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Verapamil is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Verapamil.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Verapamil.Approved
ZomepiracThe serum concentration of Verapamil can be increased when it is combined with Zomepirac.Withdrawn
ZonisamideThe risk or severity of hypotension can be increased when Verapamil is combined with Zonisamide.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Verapamil.Approved
ZosuquidarThe serum concentration of Verapamil can be increased when it is combined with Zosuquidar.Investigational
ZotepineThe metabolism of Zotepine can be decreased when combined with Verapamil.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Verapamil can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Verapamil.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Avoid natural licorice.
  • Avoid taking with grapefruit juice.
  • Take with food.

References

Synthesis Reference

Philippe Baudier, Arthur De Boeck, Jacques Fossion, "Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms." U.S. Patent US4859469, issued April, 1987.

US4859469
General References
  1. Bellamy WT: P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol. 1996;36:161-83. [PubMed:8725386]
External Links
Human Metabolome Database
HMDB0001850
KEGG Drug
D02356
KEGG Compound
C07188
PubChem Compound
2520
PubChem Substance
46508158
ChemSpider
2425
BindingDB
81939
ChEBI
77733
ChEMBL
CHEMBL6966
Therapeutic Targets Database
DAP000040
PharmGKB
PA451868
IUPHAR
2406
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Verapamil
ATC Codes
C08DA51 — Verapamil, combinationsC08DA01 — VerapamilC09BB10 — Trandolapril and verapamil
AHFS Codes
  • 24:28.92 — Miscellaneous Calcium-channel Blocking Agents
FDA label
Download (1.9 MB)
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableCrohn's Disease (CD)1
1CompletedNot AvailableDrug Dependence1
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceDrug Drug Interactions / Healthy Volunteers1
1CompletedBasic ScienceDrug-Drug Interaction (DDI) / Healthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of ASP015K1
1CompletedBasic SciencePharmacokinetics1
1CompletedDiagnosticChronic Subjective Dizziness / Vestibular Migraine1
1CompletedOtherDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentDrug-induced Surface ECG Changes1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentStroke, Ischemic1
1CompletedTreatmentType 2 Diabetes Mellitus1
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1RecruitingTreatmentCD30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
1RecruitingTreatmentStroke, Ischemic2
1WithdrawnTreatmentStroke, Ischemic1
1, 2CompletedHealth Services ResearchHealthy Volunteers1
1, 2RecruitingTreatmentPolyps, Nasal / Sinusitis1
1, 2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2Active Not RecruitingTreatmentDiabetes, Diabetes Mellitus Type 11
2CompletedTreatmentBrain Cancer / Cancers / Meningiomas1
2CompletedTreatmentDravet Syndrome1
2, 3CompletedTreatmentCluster Headache1
2, 3RecruitingTreatmentVentricular Arrythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentBMI >30 kg/m2 / High Blood Pressure (Hypertension)1
3CompletedTreatmentMania1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4CompletedPreventionRenal Stones1
4CompletedTreatmentAcute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention1
4CompletedTreatmentBMI >30 kg/m2 / General Surgery / Hypoglycemia1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
4CompletedTreatmentDiabetes Mellitus (DM) / High Blood Pressure (Hypertension) / Proteinuria1
4CompletedTreatmentHeart Disease, Ischemic1
4CompletedTreatmentHigh Blood Pressure (Hypertension)2
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Metabolic Syndromes1
4CompletedTreatmentMarfan Syndrome1
4CompletedTreatmentParoxysmal Supraventricular Tachycardia1
4CompletedTreatmentRapid Ventricular Response Atrial Fibrillation1
4RecruitingHealth Services ResearchCerebral Vasospasm1
4RecruitingTreatmentReversible cerebral vasoconstriction syndrome1
4TerminatedPreventionKeloid Scars1
4Unknown StatusTreatmentCongestive Cardiomyopathy1
4Unknown StatusTreatmentHeart Failure With Reduced Ejection Fraction (HFrEF) / Myocardial Diseases / Prophylaxis of cardiomyopathy1
Not AvailableCompletedNot AvailableCoronary Heart Disease (CHD) / Verapamil Toxicity1
Not AvailableCompletedNot AvailableErectile Dysfunction (ED)1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation1
Not AvailableTerminatedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableUnknown StatusTreatmentEpilepsies / Seizures1
Not AvailableWithdrawnTreatmentCatamenial Epilepsy1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Elan drug delivery inc
  • Gd searle llc
  • Fsc laboratories inc
  • Abraxis pharmaceutical products
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • International medication system
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Ranbaxy laboratories inc
  • Glenmark generics ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Pliva inc
  • Actavis elizabeth llc
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Warner chilcott div warner lambert co
  • Watson laboratories inc
Packagers
  • Abbott Laboratories Ltd.
  • Advanced Pharmaceutical Services Inc.
  • Alza Corp.
  • Amerisource Health Services Corp.
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • BASF Corp.
  • Cardinal Health
  • Caremark LLC
  • Comprehensive Consultant Services Inc.
  • Copley Chemical Co.
  • Dee Stevens and Son Feeder
  • Dept Health Central Pharmacy
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Duramed
  • Elan Pharmaceuticals Inc.
  • FSC Laboratories
  • GD Searle LLC
  • General Injectables and Vaccines Inc.
  • Glenmark Generics Ltd.
  • Golden State Medical Supply Inc.
  • Group Health Cooperative
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Lake Erie Medical and Surgical Supply
  • Liberty Pharmaceuticals
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Schwarz Pharma Inc.
  • Southwood Pharmaceuticals
  • Talbert Medical Management Corp.
  • Tya Pharmaceuticals
  • UDL Laboratories
  • United Research Laboratories Inc.
  • Vangard Labs Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral80 mg
Tablet, extended releaseOral180 mg/1
Tablet, extended releaseOral180 mg
Tablet, extended releaseOral240 mg/1
TabletOral120 mg
Tablet, extended releaseOral120 mg
Tablet, extended releaseOral240 mg
Tablet, extended releaseOral
Tablet, film coated, extended releaseOral
Capsule, extended releaseOral120 mg/1
Capsule, extended releaseOral180 mg/1
Capsule, extended releaseOral240 mg/1
InjectionIntravenous2.5 mg/mL
Injection, solutionIntravenous2.5 mg/mL
TabletOral120 mg/1
TabletOral240 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral240 mg/301
Tablet, film coatedOral120 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral80 mg/1
Tablet, film coated, extended releaseOral120 mg/1
Tablet, film coated, extended releaseOral180 mg/1
Tablet, film coated, extended releaseOral240 mg/1
LiquidIntravenous2.5 mg
SolutionIntravenous2.5 mg
Capsule, delayed release pelletsOral120 mg/1
Capsule, delayed release pelletsOral180 mg/1
Capsule, delayed release pelletsOral240 mg/1
Capsule, delayed release pelletsOral360 mg/1
Capsule, extended releaseOral120 mg
Capsule, extended releaseOral180 mg
Capsule, extended releaseOral240 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral200 mg/1
Capsule, extended releaseOral300 mg/1
Prices
Unit descriptionCostUnit
Verelan 360 mg 24 Hour Capsule6.82USD capsule
Verelan 360 mg cap pellet6.73USD pellet
Verelan pm 300 mg cap pellet5.87USD pellet
Verelan 240 mg 24 Hour Capsule4.76USD capsule
Verelan 240 mg cap pellet4.58USD pellet
Verelan 180 mg 24 Hour Capsule4.22USD capsule
Verelan 180 mg cap pellet4.06USD pellet
Verelan pm 200 mg cap pellet4.04USD pellet
Verelan 120 mg cap pellet3.87USD pellet
Verapamil HCl CR 300 mg 24 Hour Capsule3.82USD capsule
Isoptin sr 240 mg tablet3.32USD tablet
Verapamil hcl powder3.24USD g
Calan SR 240 mg Controlled Release Tabs3.15USD tab
Isoptin SR 240 mg Controlled Release Tabs3.14USD tab
Verelan pm 100 mg cap pellet3.13USD pellet
Calan sr 240 mg caplet3.09USD caplet
Covera-HS 240 mg 24 Hour tablet3.09USD tablet
Covera-hs 240 mg tablet sa2.97USD tablet
Isoptin sr 180 mg tablet2.9USD tablet
Calan SR 180 mg Controlled Release Tabs2.8USD tab
Isoptin SR 180 mg Controlled Release Tabs2.74USD tab
Calan sr 180 mg caplet2.7USD caplet
Verapamil HCl CR 200 mg 24 Hour Capsule2.62USD capsule
Isoptin sr 120 mg tablet2.29USD tablet
Calan SR 120 mg Controlled Release Tabs2.27USD tab
Covera-HS 180 mg 24 Hour tablet2.2USD tablet
Isoptin SR 120 mg Controlled Release Tabs2.16USD tab
Calan sr 120 mg caplet2.13USD caplet
Covera-hs 180 mg tablet sa2.11USD tablet
Verapamil HCl CR 360 mg 24 Hour Capsule2.1USD capsule
Verapamil HCl CR 100 mg 24 Hour Capsule2.04USD capsule
Isoptin Sr 240 mg Sustained-Release Tablet2.03USD tablet
Calan sr 240 mg caplet sa1.77USD caplet
Verapamil HCl CR 240 mg 24 Hour Capsule1.69USD capsule
Verapamil HCl CR 240 mg Controlled Release Tabs1.6USD tab
Calan 120 mg tablet1.56USD tablet
Isoptin Sr 180 mg Sustained-Release Tablet1.52USD tablet
Verapamil HCl CR 180 mg 24 Hour Capsule1.5USD capsule
Calan sr 180 mg caplet sa1.46USD caplet
Verapamil HCl CR 120 mg 24 Hour Capsule1.43USD capsule
Verapamil HCl CR 180 mg Controlled Release Tabs1.41USD tab
Isoptin Sr 120 mg Sustained-Release Tablet1.34USD tablet
Calan 80 mg tablet1.25USD tablet
Verapamil 2.5 mg/ml vial1.18USD ml
Verapamil HCl CR 120 mg Controlled Release Tabs1.12USD tab
Apo-Verap Sr 240 mg Sustained-Release Tablet0.91USD tablet
Mylan-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Novo-Veramil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Pms-Verapamil Sr 240 mg Sustained-Release Tablet0.91USD tablet
Calan 40 mg tablet0.76USD tablet
Apo-Verap Sr 120 mg Sustained-Release Tablet0.72USD tablet
Mylan-Verapamil Sr 120 mg Sustained-Release Tablet0.72USD tablet
Verapamil HCl 120 mg tablet0.71USD tablet
Apo-Verap Sr 180 mg Sustained-Release Tablet0.69USD tablet
Mylan-Verapamil Sr 180 mg Sustained-Release Tablet0.69USD tablet
Verapamil HCl 80 mg tablet0.56USD tablet
Apo-Verap 120 mg Tablet0.45USD tablet
Mylan-Verapamil 120 mg Tablet0.45USD tablet
Nu-Verap 120 mg Tablet0.45USD tablet
Verapamil 120 mg tablet0.39USD tablet
Verapamil 80 mg tablet0.31USD tablet
Verapamil HCl 40 mg tablet0.29USD tablet
Apo-Verap 80 mg Tablet0.29USD tablet
Mylan-Verapamil 80 mg Tablet0.29USD tablet
Nu-Verap 80 mg Tablet0.29USD tablet
Verapamil 40 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5785994No1992-10-222009-10-22Us
US6096339No1997-04-042017-04-04Us

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)243-246 °C at 1.00E-02 mm HgPhysProp
water solubility4.47 mg/LNot Available
logP3.79HANSCH,C ET AL. (1995)
Caco2 permeability-4.58ADME Research, USCD
pKa8.92SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP5.23ALOGPS
logP5.04ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)9.68ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.95 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity132.65 m3·mol-1ChemAxon
Polarizability51.7 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9371
Blood Brain Barrier+0.6323
Caco-2 permeable+0.738
P-glycoprotein substrateSubstrate0.7874
P-glycoprotein inhibitor IInhibitor0.9056
P-glycoprotein inhibitor IIInhibitor0.855
Renal organic cation transporterInhibitor0.6259
CYP450 2C9 substrateNon-substrate0.8029
CYP450 2D6 substrateNon-substrate0.8706
CYP450 3A4 substrateSubstrate0.7657
CYP450 1A2 substrateNon-inhibitor0.9553
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9181
Ames testNon AMES toxic0.8393
CarcinogenicityNon-carcinogens0.6463
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4137 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7687
hERG inhibition (predictor II)Inhibitor0.8188
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0udi-3519000000-b5e0b9e0caac5cb57222
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-004l-0702900000-6a46ea2d5eed6d8b01eb
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-0006-4109800000-80d342090a0be3344e82
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-054w-0954400000-2def387c7c93ab211423
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-0a4i-0000900000-980b47834e505d54a0e6
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-014i-0900000000-d9c344fee7b45b4030e6
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0gb9-0914000000-070bdb975910e9aae99c
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-03di-0390000000-f41d80462c5d06c4f001
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0097-2980000000-9a2ab0bcab33f7eaac6b
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0uxr-0900000000-252a9989a8511cb2db80
LC-MS/MS Spectrum - LC-ESI-IT (LC/MSD Trap XCT, Agilent Technologies) , PositiveLC-MS/MSsplash10-0f79-0900000000-4fd6ca2c6c19c3bbf8f0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000900000-4365a47b2dc2f86bb272
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0000900000-e6a2b357160bf5b92c22
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-066r-0902400000-d8eac2ccd0a767c7e432
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0901000000-688f3c2345c5d9ccb8a5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0900000000-cd09f8a2be876936f662
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-76641dd6dbc5cb05e79a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000900000-05ea95eb1f39b6515212
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0902600000-a675e624692c25472ce8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0901000000-70d820628d2613557239
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-e3ca24cf75d574df08a8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uyi-0900000000-f3a9fa002c56d3e5689a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zg0-2900000000-101e077b890671063633
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0000900000-84b4516ac84e6912cc15
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-066r-0902600000-bc1701c307e45ee4dcd7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0901000000-6fbdab598bcb6147a4bf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0gb9-0900000000-ce61116806eaa908681c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0900000000-ad3f25e02a7c8e66fb6a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgr-2900000000-792b9009086561f6c398
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-e7a5a3f8c88dc40683fd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-4cde9a4b3a4f83d16afc
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-9a5c5240148f82cc6add
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-066r-0902800000-ae024239c46b33917426
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0901000000-81d1159b3102cff76218
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-2411d65dfe09741dde81
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0gb9-0914000000-0463345a8ab0de7aa99e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0900000000-42074ab645b7af0ef79f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zgi-0900000000-20360f78435d5f482709
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0819000000-7f68ebd6e344adf12101
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0918000000-d3727bbe601b80eabfb3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0100900000-0a928f78000f291f031d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-066r-0902600000-40f800e4a364d9ca214c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0900000000-4dea228d69d59705fc18
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0500900000-c0bc440571b30d4b5b27
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066r-0900300000-47a59c15bdbcbc62d6c6
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylbutylamines
Direct Parent
Phenylbutylamines
Alternative Parents
Dimethoxybenzenes / Phenylpropanes / Phenethylamines / Phenoxy compounds / Anisoles / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Nitriles / Organopnictogen compounds
show 1 more
Substituents
Phenylbutylamine / Dimethoxybenzene / O-dimethoxybenzene / Phenethylamine / Phenylpropane / Anisole / Phenol ether / Phenoxy compound / Methoxybenzene / Alkyl aryl ether
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amino compound, aromatic ether, nitrile, polyether (CHEBI:77733)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004 Nov;66(5):1236-47. Epub 2004 Jul 30. [PubMed:15286207]
  2. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638]
  3. Patel MK, Clunn GF, Lymn JS, Austin O, Hughes AD: Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells. Br J Pharmacol. 2005 Jul;145(6):811-7. [PubMed:15880143]
  4. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1F
Uniprot ID
O60840
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1F
Molecular Weight
220675.9 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB1
Uniprot ID
Q02641
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-1
Molecular Weight
65712.995 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB3
Uniprot ID
P54284
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-3
Molecular Weight
54531.425 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB4
Uniprot ID
O00305
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-4
Molecular Weight
58168.625 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1I
Uniprot ID
Q9P0X4
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1I
Molecular Weight
245100.8 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Freeze BS, McNulty MM, Hanck DA: State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug;70(2):718-26. Epub 2006 May 12. [PubMed:16699084]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1B
Uniprot ID
Q00975
Uniprot Name
Voltage-dependent N-type calcium channel subunit alpha-1B
Molecular Weight
262493.84 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Duan JJ, Ma JH, Zhang PH, Wang XP, Zou AR, Tu DN: Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain. Acta Pharmacol Sin. 2007 Jul;28(7):959-67. [PubMed:17588331]
  2. Cheng HC, Incardona J, McCullough B: Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. J Pharmacol Toxicol Methods. 2006 Nov-Dec;54(3):278-87. Epub 2006 Feb 28. [PubMed:16507347]
  3. Schneider J, Hauser R, Andreas JO, Linz K, Jahnel U: Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol. 2005 Apr 4;512(1):53-60. [PubMed:15814090]
  4. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC: Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol. 2004 May;36(5):701-5. [PubMed:15135665]
  5. Shimizu W, Aiba T, Antzelevitch C: Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome. Curr Pharm Des. 2005;11(12):1561-72. [PubMed:15892662]
  6. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Milberg P, Reinsch N, Osada N, Wasmer K, Monnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol. 2005 Jul;100(4):365-71. Epub 2005 Jun 10. [PubMed:15944809]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage ...
Gene Name
KCNJ11
Uniprot ID
Q14654
Uniprot Name
ATP-sensitive inward rectifier potassium channel 11
Molecular Weight
43540.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Yamada S, Kane GC, Behfar A, Liu XK, Dyer RB, Faustino RS, Miki T, Seino S, Terzic A: Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol. 2006 Dec 15;577(Pt 3):1053-65. Epub 2006 Oct 12. [PubMed:17038430]
  3. Shigeto M, Katsura M, Matsuda M, Ohkuma S, Kaku K: Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J Pharmacol Exp Ther. 2007 Jul;322(1):1-7. Epub 2007 Apr 4. [PubMed:17409272]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  2. Brown NL, Sirugue O, Worcel M: The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes. Eur J Pharmacol. 1986 Apr 9;123(1):161-5. [PubMed:2940099]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Curator comments
Inhibits receptor activity but shows little competition for binding. Likely an allosteric modulator.
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Shibata K, Hirasawa A, Foglar R, Ogawa S, Tsujimoto G: Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. [PubMed:9570190]

Enzymes

Details
1. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. [PubMed:10490933]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  4. Flockhart Table - Indiana University [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  3. Flockhart Table - Indiana University [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301]
  2. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747]
  3. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137]
  4. Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43. [PubMed:10997946]
  5. Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine. Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4. [PubMed:11031728]
  6. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287]
  7. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  8. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143]
  9. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945]
  10. Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67. [PubMed:12604704]
  11. Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8. [PubMed:12636153]
  12. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  13. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226]
  14. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]
  15. Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3. [PubMed:11454724]
  16. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369]
  17. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455]
  18. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6. [PubMed:8094615]
  19. Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol. 1997 Jan 10;53(1):17-25. [PubMed:8960059]
  20. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55. [PubMed:9205004]
  21. Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45. [PubMed:9732409]
  22. Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7. [PubMed:10075817]
  23. Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch. 1999 Apr;437(5):652-60. [PubMed:10087141]
  24. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6. [PubMed:10571255]
  25. Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52. [PubMed:10583025]
  26. Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9. [PubMed:15240100]
  27. Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25. [PubMed:15504753]
  28. Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11. [PubMed:15176077]
  29. Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81. [PubMed:12569305]
  30. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  31. Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm Res. 2004 Aug;21(8):1398-404. [PubMed:15359574]
  32. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309]
  33. Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63. [PubMed:9395229]
  34. Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35. doi: 10.1002/ijc.24885. [PubMed:19739078]
  35. Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. doi: 10.1016/j.toxlet.2009.11.018. Epub 2009 Nov 26. [PubMed:19944135]
  36. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452]
  37. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272]
  38. Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300. [PubMed:19530439]
  39. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
  40. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273]
  41. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690]
  42. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82. [PubMed:10773005]
  43. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
  44. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684]
  45. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  46. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
  47. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039]
  48. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716]
  49. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340]
  50. Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25. doi: 10.1111/j.1526-4610.2008.01298.x. [PubMed:19125880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD: Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun 1;62(11):3144-50. [PubMed:12036927]
  2. Bai J, Lai L, Yeo HC, Goh BC, Tan TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004 Feb;36(2):247-57. [PubMed:14643890]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
  2. Ohashi R, Tamai I, Nezu Ji J, Nikaido H, Hashimoto N, Oku A, Sai Y, Shimane M, Tsuji A: Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol. 2001 Feb;59(2):358-66. [PubMed:11160873]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M: Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3). Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27. [PubMed:16384552]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612]
  2. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 2004 Jun;65(6):1485-95. [PubMed:15155841]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH: Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12. [PubMed:19139163]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Wilson A. (2016). New horizons in predictive drug metabolism and pharmacokinetics. The Royal Society of Chemistry. [ISBN:978-1-84973-828-6]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:43